$6 BAT 2022 MNH Ships Stamps Death of Sir Ernest Shackleton Explora Stamps Topical Stamps Transportation BAT 2022 MNH Ships Stamps Death Ernest of Sir Shackleton Explora Long-awaited BAT 2022 MNH Ships Stamps Death Ernest of Sir Shackleton Explora Long-awaited Death,BAT,Sir,Explora,Shackleton,Stamps,Ernest,$6,2022,handicraftstoreagra.com,/Geoprumnon1040141.html,MNH,Stamps , Topical Stamps , Transportation,Ships,of Death,BAT,Sir,Explora,Shackleton,Stamps,Ernest,$6,2022,handicraftstoreagra.com,/Geoprumnon1040141.html,MNH,Stamps , Topical Stamps , Transportation,Ships,of $6 BAT 2022 MNH Ships Stamps Death of Sir Ernest Shackleton Explora Stamps Topical Stamps Transportation

BAT 2022 MNH Ships Stamps Death Ernest of Sir Shackleton Excellent Explora Long-awaited

BAT 2022 MNH Ships Stamps Death of Sir Ernest Shackleton Explora

$6

BAT 2022 MNH Ships Stamps Death of Sir Ernest Shackleton Explora

|||

Item specifics

Seller Notes:
“New, mint condition (MNH).”
Quality:
Mint Never Hinged/MNH
Theme:
Transport
Topic:
Ships, Boats
Region:
British Antarctic Territory
Year of Issue:
2011-Present
Type:
Set

BAT 2022 MNH Ships Stamps Death of Sir Ernest Shackleton Explora

Intro Pullout Text Widget

is a leading rheumatology journal from BMJ and EULAR, publishing original research, reviews and recommendations

Impact Factor: 19.103
Citescore: 28.7
All metrics >> 

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

ARD is an official journal of EULAR.

Free 6pin to 6+8pin Power Cable for HPE DL360 G6 G7 Backplane power a are provided for selected research articles and all DAVIDOFF COOL WATER BODY TALC 5.1 OZ NEW IN BOX (A41). You can keep up with the latest news via Twitter and Facebook.

Listen to the ARD podcast and subscribe in all podcast platforms, including Apple PodcastGoogle PodcastsStitcher and Spotify.

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

Latest Content

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.
 
The Author Information section provides general guidelines and requirements for specific article types.
 
Information is also provided on editorial policies and open access.

Free Lay Summaries

Are you looking for the latest rheumatology research findings presented in an easily accessible format to share with patients, carers or colleagues?

 

ARD provides free lay summaries for selected research articles and all EULAR recommendations.

 

These aim to clearly explain the results of the research studies as well as any implications for treatment of the specific condition. The summaries are written in plain language in a consistently structured format and checked for accuracy and readability by experts and patient representatives.

 

EULAR Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.

 

All EULAR recommendations are free to access

 

Each recommendation also has an accompanying US 4244-47 42c flags PNC strip of 25 Plate no. V1111. MNH SA Ne, which is also free to access.

Video Abstract

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE

To cite: Vital EM, Merrill JT, Morand EF, et al. Ann Rheum Dis. doi: 10.1136/annrheumdis-2021-221425

Read the full article here: link
Objective: To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups.

Conclusions: Overall, this study supports the consistent efficacy and safety of anifrolumab across a range of patients with moderate-to-severe SLE. In a few subgroups, small sample sizes limited conclusions from being drawn regarding the treatment benefit with
anifrolumab.

Podcasts